Talon Therapeutics Inc., of San Mateo, Calif., enrolled its first patient in a Phase I trial of Marqibo (vincristine sulfate liposomes injection) for pediatric use in acute lymphoblastic leukemia. The company said that the drug has potential for solid tumors and hematologic malignancies.